Table 4.
Comparison of the results of the PROMET study with other published large volume studies
| Patients/leads | Indications | Leads | Implant duration (months) | Success rates | Major complications | In-hospital mortality | |
|---|---|---|---|---|---|---|---|
| PROMET study | 2205/3849 | 46.0% infection | 74.8% pacemaker leads | Mean 84.7 ± 61.8 | 96.5% CPS | 1% | 1.7% (30-day mortality) |
| 54.0% non-infectious | 24.6% ICD leads | Median 74.0 | 97.0% | ||||
| 0.6% unknown | IQR (41.0–112.0) | CS | |||||
| LEXICON study | 1449/2405 | 56.9% | 70.0% pacemaker leads | Median 82.1 | 96.5% CPS | 1.4% | 1.86% |
| Infection | 29.2% ICD leads | IQR (0.4–356.8) | 97.7% | ||||
| 43.1% | 0.7% unknown | CS | |||||
| Non-infectious | |||||||
| ELECTRa study | 3510/4917 | 52.8% infection | 75.7% pacemaker leads | Mean 76.8 ± 64.8 | 95.7% CPS | 1.7% | 1.4% |
| 47.3% non-infectious | 24.3% ICD leads | Median 60.0 | 96.7% | ||||
| IQR (24.0–108.0) | CS |
CPS, complete procedural success; CS, clinical success; ICD, implantable cardioverter-defibrillator; IQR, interquartile range.